MAZE MAZE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, MAZE THERAPEUTICS INC reported revenue of n/a, net income of −$44.7M and diluted EPS of −$0.76; for the fiscal year ended December 2025 revenue was n/a.
MAZE annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$143M, net income −$131M (margin n/a), EPS −$3.05
- Fiscal year ended Dec 2024: revenue $168M, gross profit n/a, operating income $57.6M, net income $52.2M (margin 31.2%), EPS $1.25
MAZE quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$44.7M, EPS −$0.76
- Quarter ended Mar 31, 2026: revenue $20.0M, net income −$24.2M, EPS −$0.45
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$34.6M, EPS −$0.47
- Quarter ended Sep 30, 2025: revenue n/a, net income −$30.1M, EPS −$0.66
- Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$33.7M, EPS −$0.77
- Quarter ended Mar 31, 2025: revenue n/a, net income −$32.8M, EPS −$1.15
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$29.6M, EPS $22.19
- Quarter ended Sep 30, 2024: revenue $2.50M, net income −$24.8M, EPS −$10.25
- Quarter ended Jun 30, 2024: revenue $165M, net income $139M, EPS $3.22
- Quarter ended Mar 31, 2024: revenue n/a, net income −$32.5M, EPS −$13.91
MAZE cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$112M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $76.0M, share buybacks n/a
MAZE balance sheet
- Jun 30, 2026: cash $203M, total assets $532M, total liabilities $78.5M, shareholders' equity $453M, long-term debt $39.0M
- Mar 31, 2026: cash $199M, total assets $420M, total liabilities $78.0M, shareholders' equity $342M, long-term debt $38.8M
- Dec 31, 2025: cash $189M, total assets $397M, total liabilities $42.2M, shareholders' equity $355M
- Sep 30, 2025: cash $317M, total assets $422M, total liabilities $42.6M, shareholders' equity $379M
- Jun 30, 2025: cash $265M, total assets $304M, total liabilities $41.3M, shareholders' equity $262M
- Mar 31, 2025: cash $294M, total assets $333M, total liabilities $40.8M, shareholders' equity $292M
- Dec 31, 2024: cash $197M, total assets $241M, total liabilities $43.6M, shareholders' equity −$311M
Is MAZE profitable?
No. MAZE THERAPEUTICS INC lost $134M over the last four quarters.
What is MAZE's EPS?
Diluted earnings per share over the last four quarters were −$2.34; −$0.76 in the latest quarter.